Catherine Moukheibir - Apr 6, 2022 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Role
Director
Signature
/s/ Matthias Bodenstedt, Attorney-in-fact for Catherine Moukheibir
Stock symbol
MLTX
Transactions as of
Apr 6, 2022
Transactions value $
$0
Form type
4
Date filed
5/5/2022, 05:47 PM
Previous filing
Apr 15, 2022
Next filing
Jun 3, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLTX Option to Buy Award $0 +45K $0.00 45K Apr 6, 2022 Class A ordinary shares, par value $0.0001 per share 45K $12.25 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Ms. Moukheibir was granted 45,000 options on April 6, 2022 pursuant to the MoonLake Immunotherapeutics 2022 Equity Incentive Plan (the "Plan"), vesting one-third on each of April 6, 2023, April 6, 2024 and April 6, 2025, in each case, subject to the terms of the Plan. Each option represents the right to acquire one Class A ordinary share, par value $0.0001 per share, of the Issuer.